The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
KIMS already have a multi-specialty hospital and gastro unit at Vizag
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dyslipidemia is a critical risk factor for cardiovascular diseases
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Subscribe To Our Newsletter & Stay Updated
